Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 66-year-old man with metastatic prostatic carcinoma treated with high-dose (5 mg) diethylstilbestrol therapy underwent orchiectomy to allow discontinuation of estrogen. An extensive ecchymosis developed postoperatively in an area covered by elastic dressing tape; subsequently, it was learned that the patient had a recent history of frequent ecchymoses with mild trauma that proceeded to vesiculation. His alpha2-antiplasmin level was 132 percent, fibrin split products 4 micrograms/ml, and fibrinogen 293 mg/dl; routine coagulation results were normal. However, the level of releasable vascular plasminogen activator in a specimen drawn prior to surgery was 3.6 CTA units/ml, the highest value ever reported in this laboratory.
 ...
PMID:Increased releasable vascular plasminogen activator and a bleeding diathesis. 654 Sep 87

We describe a simple assay of plasminogen activator in which the enzyme reacts with a mixture of plasminogen and H-D-valyl-L-leucyl-L-lysine-p-nitroanilide for 1 h at 37 degrees C after which the absorbance is measured at 405 nm. The method detects as little as 2 CTA milliunits of activator and is linear over a 100-fold range of enzyme concentration. The new procedure has been used successfully for the assay of activator in breast tumor cytosols, cell culture supernatants, and pleural or ascitic fluids. Thirty-two biological samples have been assayed for plasminogen activator activity with both the spectrophotometric method and a classical fibrinolytic technique using radiolabeled fibrin. Although the two series of results are significantly correlated, the activities measured with the former assay are significantly different from those determined with the latter. It is shown that the spectrophotometric method is, in many respects, superior to the fibrinolytic procedure.
 ...
PMID:A simple spectrophotometric assay of plasminogen activator: comparison with the fibrinolytic method. 654 36

These studies describe an assay of whole blood clot lysis as measured by release of 125I-fibrinogen degradation products. Optimal rates of lysis were obtained at 37 degrees C in 10-12 mM EDTA or 3,8% citrate and 4 u of thrombin/ml. Eighteen normal subjects and eight patients (six with recurrent deep vein thrombosis, one with thrombasthenia, and one with hepatitis and resolving portal vein thrombosis) were studied using this assay. The clots of seventeen of the eighteen normal subjects were 50% lysed at 40 hours. The clots of the patients with venous thrombosis and thrombasthenia did not lyse whereas the clots of the patient with hepatitis, resolving portal vein thrombosis and a high plasminogen activator level (0.32 CTA units) were 100% lysed at 4.5 hrs.
 ...
PMID:Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation. 682 Jan 94

Although poly(lactide) (PLA), when used as biomaterials, possesses many good properties, its high hydrophobicity and slow degradation may hinder its applications. In this work, a novel star-like oligomeric silsesquioxane-(poly(2-dimethylaminoethyl methacrylate)-b-poly(d-lactide))8 (POSS-(PDMAEMA-b-PDLA)8) was first synthesized through a three-step procedure that involves Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization of DMAEMA initiated by the macroinitiator POSS-8-CTA, and then conversion of the trithiocarbonated end groups on PDMAEMA arms into hydroxyl groups by a combination of aminolysis and Michael addition followed by controlled ring-opening polymerization of D-LA. In the next step, the synthesized hybrid copolymer POSS-(PDMAEMA-b-PDLA)8 was blended with PLLA in solution to form nanocomposites to further modify the thermo-mechanical and degradation properties of PLLA. It was noted that the outer PDLA shell could facilitate POSS-(PDMAEMA-b-PDLA)8 to be well-dispersed in PLLA matrix through stereocomplex (SC) interaction, and the inner PDMAEMA shell endowed PLLA with good hydrophilicity. The SC formation between POSS-(PDMAEMA-b-PDLA)8 and PLLA was confirmed by differential scanning calorimetry (DSC) and X-ray diffraction (XRD) analyses. The surface wettability of the PLLA was enhanced due to the presence of hydrophilic PDMAEMA segments and the contact angle values decreased with increasing amount of PDMAEMA in the nanocomposites. Meanwhile, controlled degradation of PLLA in a faster pace was achieved when the nanocomposites were incubated in different pH solutions, indicating its potential in specific biomedical applications.
 ...
PMID:Synthesis of star-like hybrid POSS-(PDMAEMA-b-PDLA)8 copolymer and its stereocomplex properties with PLLA. 2848 19

The ischemic penumbra is a transient and potentially reversible condition. Therefore, infarct progression and its counterpart penumbral salvage are highly variable and result from the interaction of 3 major factors: collateral flow, revascularization delay and success. Multimodal brain imaging now offers in clinical practice an exhaustive characterization of the acute ischemic injury: vessel site occlusion, infarction/critical hypoperfusion volume, and collateral flow. From 1995 to 2015, IV alteplase administered within 4.5hours after the onset of acute BI diagnosed by the absence of hemorrhage on a non-contrast head CT scan has been the only approved revascularization treatment. Over the past 2years, 6 randomized trials have confirmed the benefit of a thrombectomy performed within 6-8 hours after the onset of an acute anterior BI downstream of an ICA/M1 occlusion. The recommended imaging modality for such patients remains a NCCT to exclude an hemorrhage and a CTA to confirm the proximal vessel occlusion. As a consequence, in the absence of collateral or penumbral imaging, studies and meta-analyses, have emphasized the importance of treatment delay on the outcome of patient after a revascularisation treatment (tPA/thrombectomy). These findings have supported the development of mobile stroke unit for tPA administration and the direct transfer of the patients eligible to thrombectomy to a comprehensive stroke center, bypassing primary stroke unit and sometimes conventional neuro imaging. In addition randomized controlled trial that did enroll patients based on the presence of a target mismatch on multimodal imaging demonstrated a higher benefit of revascularisation treatment by comparison with those who did not.This year the results of the randomized trial, Diffusion-weighted Imaging or Computerized Tomography Perfusion Assessment with Clinical Mismatch in the Triage of Wake-up and Late Presenting Strokes Undergoing Neurointervention with Trevo (DAWN)demonstrated for the first time that revascularization treatment for BI complicating an ICA or a proximal MCA M1 was still beneficial from 6 to 24hours after onset among patient who did have per their clinical exam and the multimodal brain imaging have a persistent penumbra. With this as a background we will discuss the yield of imaging for the selection of patients for a revascularization therapy.
 ...
PMID:Which imaging before reperfusion strategy? 2903 36


<< Previous 1 2